PROJECT SUMMARY
Prostate cancer (PCa) is one of the most prevalent forms of malignancy and the second most common cause of
cancer-related death in men. Uncovering novel mechanisms that control prostatic tumorigenesis may advance
development of more effective therapeutics to treat this life-threatening disease. Heparan sulfate (HS), a type of
polysaccharide, is an essential component of the cell microenvironment and plays an important role in cell-cell
and cell-matrix interaction and signaling. Recent studies reported that expression of HS-synthesizing and
modifying genes are dysregulated in human PCa specimens. Currently, it is not known what causes this
aberrant HS expression, and, more importantly, what are the functional consequences of the aberrant HS
expression in prostatic tumorigenesis. In this application, we propose to test our novel hypothesis “Pten-loss
in prostate leads to aberrant HS expression creating a unique cellular environment that potentiates
prostatic tumorigenesis” by pursuing the following three Specific Aims: 1. Determine if aberrant HS
expression in human prostate epithelial cells is induced by Pten-loss and correlates with malignancy of Pten-
null human PCa; 2. Determine if aberrant HS expression induced by Pten-loss potentiates prostatic
tumorigenesis; 3. Determine if aberrant HS expression induced by Pten-loss potentiates PCa-associated
inflammation. The proposed studies will use both novel and established genetic, cellular, biochemical and
bioinformatics approaches in conjunction with in vitro cell function and in vivo human and mouse PCa models.
These serial investigations are anticipated to delineate a novel mechanism that drives aberrant HS expression
in PCa, reveal the aberrant HS expression to be a novel biomarker for PCa early diagnosis and prognosis, and
elucidate the pivotal roles and their underlying molecular mechanisms of the aberrant HS expression in prostatic
tumorigenesis, which likely will contribute to the development of novel therapeutics for PCa treatment.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE
This proposal is highly relevant to public health as the proposed studies are expected to delineate a novel
mechanism that drives aberrant heparan sulfate expression in prostate cancer, reveal the aberrant heparan
sulfate expression to be a novel biomarker for early diagnosis and prognosis of prostate cancer, and to
elucidate the pivotal roles and underlying molecular mechanisms of the aberrant heparan sulfate expression in
prostatic tumorigenesis, which likely will contribute to the development of novel therapeutics for prostate cancer
treatment.
NIH Spending Category
CancerProstate CancerUrologic Diseases
Project Terms
AblationAdvanced DevelopmentAffectAnabolismBiochemicalBioinformaticsBiological AssayCXCR4 geneCancer Cell GrowthCancer EtiologyCancerousCell physiologyCell surfaceCellsCellular StructuresCessation of lifeCoupledDevelopmentDiseaseEXT1 geneEarly DiagnosisEnvironmentEnzymesEpithelial CellsEpitopesEventExtracellular MatrixFGF1 geneFGFR1 geneGene ExpressionGenesGeneticGrowthHeparitin SulfateHumanIL8RB geneIn VitroInfiltrationInflammationInflammatoryInvestigationKnock-outLifeLigandsMalignant NeoplasmsMalignant neoplasm of prostateMeasuresModelingMolecularMusMutateMyeloid-derived suppressor cellsPlayPolymersPolysaccharidesPrognosisProstateProstate Cancer therapyProstaticProteinsPublic HealthReportingRoleSignal TransductionSpecificitySpecimenStructureSystemTestingTumor Suppressor GenesXenograft procedureautocrinecancer initiationcell motilitychemokinein vivomenmouse modelneutralizing antibodynovelnovel markernovel therapeuticsoverexpressionprostate cancer cellprostate cancer cell lineprostate cancer modelpublic health relevancerecruittherapeutically effectivetumortumor progressiontumorigenesis
No Sub Projects information available for 5U01CA225784-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01CA225784-05
Patents
No Patents information available for 5U01CA225784-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01CA225784-05
Clinical Studies
No Clinical Studies information available for 5U01CA225784-05
News and More
Related News Releases
No news release information available for 5U01CA225784-05
History
No Historical information available for 5U01CA225784-05
Similar Projects
No Similar Projects information available for 5U01CA225784-05